In addition, due to certain conversions of Series E Convertible Preferred Stock and exercises of Series C Warrants since our last update on September 18, 2015, Great Basin Scientific, Inc. (NASDAQ:GBSN) now has 190,630,634 issued and outstanding shares of common stock, par value $0.001 per share (“Common Stock”). Accordingly, the Company no longer has sufficient authorized unissued shares of Common Stock to settle the exercises of the Series C Warrants, resulting in an Authorized Share Failure. In light of the Authorized Share Failure, the Company will follow the procedures outlined in its Current Report on Form 8-K filed September 21, 2015.
Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious disease. The Company has a commercially available test, a diagnostic test for clostridium difficile (C. diff), which received clearance from the Food and Drug Administration (FDA).
Great Basin Scientific, Inc. (NASDAQ:GBSN) belongs to Healthcare sector. Its weekly performance is 8.15%. On last trading day company shares ended up at $0.08. Great Basin Scientific, Inc. (NASDAQ:GBSN) distance from 50-day simple moving average (SMA50) is -94.56%.
Genocea Biosciences (NASDAQ:GNCA)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a note issued to investors on Monday, Marketbeat.com reports. They presently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 70.94% from the stock’s previous close.
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates, which are GEN-001, GEN-002 and GEN-005 in pre-clinical development for diseases, including genital herpes, chlamydia and malaria. It also creates a library of every protein in the proteome of the pathogen of interest. It uses ATLAS as a throughput engine to screen human T cells to identify relevant T cell vaccine antigens.
Genocea Biosciences, Inc. (NASDAQ:GNCA) shares moved down -15.71% in last trading session and ended the day at $7.35. GNCA return on assets is -63.40%. Genocea Biosciences, Inc. (NASDAQ:GNCA) quarterly performance is -43.24%.
MDC Partners Inc. (NASDAQ:MDCA) will present at the Deutsche Bank 23rd Annual Leveraged Finance Conference at The Phoenician in Scottsdale, Arizona, on Wednesday, September 30, 2015. David Doft, Chief Financial Officer, will present at 3:35 PM, Mountain Standard Time (MST) / 6:35 PM, Eastern Daylight Time (EDT).
MDC Partners is one of the fastest-growing and most influential marketing and communications networks in the world. Its 50+ advertising, public relations, branding, digital, social and event marketing agencies are responsible for some of the most memorable and engaging campaigns for the world’s most respected brands. By leveraging technology, data analytics, insights, and strategic consulting solutions, MDC Partners drives measurable results and optimizes return on marketing investment for over 1,500 clients worldwide.
On 28 September, MDC Partners Inc. (NASDAQ:MDCA) shares moved down -4.23% and was closed at $17.87. MDCA EPS growth in last 5 year was 30.50%. MDC Partners Inc. (NASDAQ:MDCA) year to date (YTD) performance is -19.02%.
Working Mother magazine today named Discovery Communications, Inc. (NASDAQ:DISCA) for the 16th consecutive year, as one of the 2015 Working Mother 100 Best Companies for its commitment to progressive workplace programs, including advancement of women, flexibility, child care and paid parental leave. The 100 Best Companies are featured in the October/November issue of Working Mother and on workingmother.com.
Discovery Communications is the world’s #1 pay-TV programmer reaching nearly 3 billion cumulative subscribers in more than 220 countries and territories. For 30 years Discovery has been dedicated to satisfying curiosity and entertaining viewers with high-quality content through its global television brands, led by Discovery Channel, TLC, Animal Planet, Investigation Discovery, Science and Turbo/Velocity, as well as U.S. joint venture network OWN: Oprah Winfrey Network. Discovery controls Eurosport, the leading pan-regional sports entertainment destination across Europe and Asia-Pacific.
Discovery Communications, Inc. (NASDAQ:DISCA) ended the last trading day at $27.78. Company weekly volatility is calculated as 2.62% and price to cash ratio as 49.27. Discovery Communications, Inc. (NASDAQ:DISCA) showed a weekly performance of -3.58%.
Attunity Ltd. (NASDAQ : ATTU), a leading provider of data management software solutions, announced that its Chairman and Chief Executive Officer, Shimon Alon, presented at the 6th Annual Craig-Hallum Alpha Select Conference at 9:20am EDT on Thursday, September 17, 2015, at the Convene Conference Center, 730 Third Avenue, New York, NY.
Attunity is a leading provider of data management software solutions that enable access, management, sharing and distribution of data, including Big Data, across heterogeneous enterprise platforms, organizations, and the cloud. Our software solutions include data replication, data flow management, test data management, change data capture (CDC), data connectivity, enterprise file replication (EFR), managed file transfer (MFT), data warehouse automation, data usage analytics, and cloud data delivery.
Attunity, Ltd. (NASDAQ:ATTU) shares moved down -4.66% in last trading session and ended the day at $13.70. ATTU Gross Margin is 88.10% and its return on assets is -3.30%. Attunity, Ltd. (NASDAQ:ATTU) quarterly performance is 5.38%.